In a preclinical mouse model of intrahepatic cholangiocarcinoma (ICC), PD-1 treatment simultaneously blocked METTL1 and its downstream chemokine pathway (CXCL8 in the human body and CXCL5 in the mouse body), boosting the immune response in the mice [224]. This evidence concerns the gene CXCL8 and intrahepatic cholangiocarcinoma.